研究单位：[1]Ruijin Hospital[2]Affiliated Hospital of Hebei University Baoding,China[3]Cancer Hospital Chinese Academy of Medical Sciences Beijing,China[4]Sichuan Cancer Hospital & Institute Chengdu,China[5]Heping Hospital Affiliated to Changzhi Medical College Changzhi,China[6]Sichuan Provincial People's Hospital Chengdu,China[7]The Affiliated Hospital of Guizhou Medical University Guiyang,China[8]Hainan Cancer Hospital Haikou,China[9]Cancer Hospital of the University of Chinese Academy of Sciences Hangzhou,China[10]The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou,China
研究目的：
The study is being conducted to evaluate the efficacy,safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
